Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy

Somatostatin receptor-2 (SSTR2) is expressed on cell surface of neuroendocrine neoplasias; its presence is exploited for the delivery of peptide receptor radionuclide therapy (PRRT). Patients with no or low expression of SSTR2 are not candidates for PRRT. SSTR2 promotor undergoes epigenetic modifica...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2022-11, Vol.176, p.110-120
Hauptverfasser:	Evans, Joanne S., Beaumont, Jamie, Braga, Marta, Masrour, Nahal, Mauri, Francesco, Beckley, Alice, Butt, Shamus, Karali, Christina S., Cawthorne, Chris, Archibald, Stephen, Aboagye, Eric O., Sharma, Rohini
Format:	Artikel
Sprache:	eng
Schlagworte:	Azacitidine - pharmacology Biocompatibility Biomarkers Cell surface Demethylation Epigenesis, Genetic Epigenetic modification Epigenetics Fluorine isotopes Gene expression Guadecitabine Humans In vivo methods and tests Methylation Neuroendocrine Tumors - drug therapy Neuroendocrine Tumors - genetics Neuroendocrine Tumors - radiotherapy Neuroendocrine tumours Octreotide - therapeutic use Peptide receptor radionuclide therapy Peptides Positron emission Positron emission tomography Potentiation Radiation therapy Radioisotopes Receptors Receptors, Somatostatin - genetics Receptors, Somatostatin - metabolism Somatostatin Somatostatin receptors SSTR2 Toxicity Translation Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!